"The big picture: The Danish drugmaker said participants in a 64-week clinical trial saw an average weight loss of about 17% if they stayed on the daily pill, reduced their calorie intake and increased exercise. That's compared to 3% average weight loss among trial participants who received a placebo. Between the lines: The active ingredient in oral Wegovy will be manufactured in North Carolina, Novo Nordisk said."
"Novo Nordisk and its rival Eli Lilly have waged a two-horse race to dominate the anti-obesity market, with an eye toward expanding to patients who may feel uncomfortable with using an injectable drug. The pills are expected to be easier to make, reducing the chances of shortages that have plagued the sector. "We are confident and ready to meet demand so patients can count on timely access to Wegovy pill," Dave Moore, executive vice president of U.S. operations, said in a statement."
Oral Wegovy will be available as a 1.5-milligram starting dose in early January at $149 per month. A 64-week clinical trial showed participants on the daily pill who reduced calories and increased exercise lost about 17% of body weight on average, versus about 3% for placebo recipients. The active ingredient for the pill will be manufactured in North Carolina. Novo Nordisk and Eli Lilly are competing to dominate the anti-obesity market and to attract patients who prefer pills over injectables. The pills are expected to be easier to produce, lowering risk of shortages. Company leadership stated readiness to meet demand.
Read at Axios
Unable to calculate read time
Collection
[
|
...
]